Skip to main content

Peer Review reports

From: Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis

Original Submission
10 Oct 2024 Submitted Original manuscript
16 Oct 2024 Author responded Author comments - Nan Zhang
17 Oct 2024 Author responded Author comments - Nan Zhang
Resubmission - Version 2
16 Oct 2024 Submitted Manuscript version 2
18 Oct 2024 Author responded Author comments - Nan Zhang
Resubmission - Version 3
18 Oct 2024 Submitted Manuscript version 3
1 Dec 2024 Reviewed Reviewer Report
2 Feb 2025 Reviewed Reviewer Report - Roberto Buonaiuto
9 Mar 2025 Author responded Author comments - Nan Zhang
Resubmission - Version 4
9 Mar 2025 Submitted Manuscript version 4
11 Apr 2025 Author responded Author comments - Nan Zhang
Resubmission - Version 5
11 Apr 2025 Submitted Manuscript version 5
Publishing
21 Apr 2025 Editorially accepted
8 May 2025 Article published 10.1186/s12885-025-14194-w

You can find further information about peer review here.

Back to article page